MedDataX Logo

Variation of Genes Controlling Carbohydrate and Lipid Metabolism

NCT ID: NCT03310502

Last Updated: 2021-10-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

2050 participants

Study Classification

OBSERVATIONAL

Study Start Date

2002-04-17

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aim of the study is to investigate genes regulating glucose and lipid metabolism in subjects whose glucose metabolism, lipid metabolism, blood flow, or body fat distribution has been measured using positron emission tomography (PET), magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS) or computed tomography (CT) as part of their previous participation in clinical trials conducted at Turku PET Centre.

By combining information from PET, MRI, CT, proteomics, metabolomics and genetics analyses we aim to find connection between genetic variation and metabolic and cardiovascular disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The data is collected as a separate part of the clinical imaging study protocols using a separate inform consent approved by the local ethics committee. The participation for this study consists of drawing whole blood, serum and plasma samples for genetics, proteomics and metabolomics analyses. The results from these studies are combined with baseline data from the original clinical imaging studies to find connections between genetic variation, metabolism, blood flow and body fat distribution in a cross-sectional setting.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2 Cardiovascular Diseases Obesity Insulin Resistance Lipid Metabolism Disorders PreDiabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Previous participation of studies measuring glucose metabolism, lipid metabolism, bloow flow and adiposity at Turku PET Centre

Exclusion Criteria

\-
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Eastern Finland

OTHER

Sponsor Role collaborator

Kuopio University Hospital

OTHER

Sponsor Role collaborator

University of Turku

OTHER

Sponsor Role collaborator

Turku University Hospital

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pirjo Nuutila

Professor, chief physician

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pirjo R Nuutila, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Turku PET centre, TurkuUH

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Turku PET Centre (Turku University Hospital)

Turku, , Finland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Finland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Pirjo R Nuutila, MD, PhD

Role: CONTACT

[email protected]
+35823131868

Miikka Honka, MSc

Role: CONTACT

[email protected]
+35823132798

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Pirjo Nuutila, M.D., Ph.D.

Role: primary

[email protected]
+358 2 2611 868

References

Explore related publications, articles, or registry entries linked to this study.

Tuomola N, Rebelos E, Latva-Rasku A, Bucci M, Immonen H, Saunavaara V, Laine S, Sjoros T, Garthwaite T, Raiko JRH, Fernandes Silva L, Virtanen KA, Hannukainen JC, Ala-Korpela M, Kalliokoski KK, Heinonen IHA, Nuutila P, Honka MJ. Mildly elevated liver lipid content is characterised by reduced insulin sensitivity. JHEP Rep. 2025 Aug 6;7(11):101535. doi: 10.1016/j.jhepr.2025.101535. eCollection 2025 Nov.

Reference Type DERIVED
PMID: 41113123 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CMgene

Identifier Type: -

Identifier Source: org_study_id